Curevac, GSK’s new COVID variant vaccine effective in animal studies
FRANKFURT, April 21 (Reuters) - CureVac  and GSK's  second-generation mRNA vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on rodents, CureVac said. A study in…